243 related articles for article (PubMed ID: 36840779)
1. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease.
Stallhofer J; Guse J; Kesselmeier M; Grunert PC; Lange K; Stalmann R; Eckardt V; Stallmach A
Int J Colorectal Dis; 2023 Feb; 38(1):54. PubMed ID: 36840779
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease.
Mahmoud R; Schultheiss HP; Louwers J; van der Kaaij M; van Hellemondt B; Mahmmod N; van Boeckel P; Jharap B; Fidder H; Oldenburg B
Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2577-2587.e6. PubMed ID: 35101632
[TBL] [Abstract][Full Text] [Related]
3. Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies.
Anjie SI; Hanzel J; Gecse KB; D'Haens GR; Brandse JF
Scand J Gastroenterol; 2024; 59(2):169-175. PubMed ID: 37961895
[TBL] [Abstract][Full Text] [Related]
4. Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients.
Colman RJ; Portocarrero-Castillo A; Chona D; Hellmann J; Minar P; Rosen MJ
Inflamm Bowel Dis; 2021 Mar; 27(4):507-515. PubMed ID: 32426829
[TBL] [Abstract][Full Text] [Related]
5. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
Strik AS; van den Brink GR; Ponsioen C; Mathot R; Löwenberg M; D'Haens GR
Aliment Pharmacol Ther; 2017 Apr; 45(8):1128-1134. PubMed ID: 28230306
[TBL] [Abstract][Full Text] [Related]
6. Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
Chanchlani N; Lin S; Auth MK; Lee CL; Robbins H; Looi S; Murugesan SV; Riley T; Preston C; Stephenson S; Cardozo W; Sonwalkar SA; Allah-Ditta M; Mansfield L; Durai D; Baker M; London I; London E; Gupta S; Di Mambro A; Murphy A; Gaynor E; Jones KDJ; Claridge A; Sebastian S; Ramachandran S; Selinger CP; Borg-Bartolo SP; Knight P; Sprakes MB; Burton J; Kane P; Lupton S; Fletcher A; Gaya DR; Colbert R; Seenan JP; MacDonald J; Lynch L; McLachlan I; Shields S; Hansen R; Gervais L; Jere M; Akhtar M; Black K; Henderson P; Russell RK; Lees CW; Derikx LAAP; Lockett M; Betteridge F; De Silva A; Hussenbux A; Beckly J; Bendall O; Hart JW; Thomas A; Hamilton B; Gordon C; Chee D; McDonald TJ; Nice R; Parkinson M; Gardner-Thorpe H; Butterworth JR; Javed A; Al-Shakhshir S; Yadagiri R; Maher S; Pollok RCG; Ng T; Appiahene P; Donovan F; Lok J; Chandy R; Jagdish R; Baig D; Mahmood Z; Marsh L; Moss A; Abdulgader A; Kitchin A; Walker GJ; George B; Lim YH; Gulliver J; Bloom S; Theaker H; Carlson S; Cummings JRF; Livingstone R; Beale A; Carter JO; Bell A; Coulter A; Snook J; Stone H; Kennedy NA; Goodhand JR; Ahmad T;
Aliment Pharmacol Ther; 2022 Oct; 56(8):1250-1263. PubMed ID: 36039036
[TBL] [Abstract][Full Text] [Related]
7. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
8. BMI is important in predicting the loss of response in inflammatory bowel disease patients on tumour necrosis factor-α inhibitors.
Chuck W; Shadbolt BF; Nordin F; Subramaniam K
Eur J Gastroenterol Hepatol; 2022 Jun; 34(6):622-629. PubMed ID: 35352694
[TBL] [Abstract][Full Text] [Related]
9. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
[TBL] [Abstract][Full Text] [Related]
10. Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease.
Hong SW; Park J; Yoon H; Yang HR; Shin CM; Park YS; Kim N; Lee DH; Kim JS
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S9-S17. PubMed ID: 32580540
[TBL] [Abstract][Full Text] [Related]
11. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.
Ungar B; Kopylov U; Engel T; Yavzori M; Fudim E; Picard O; Lang A; Williet N; Paul S; Chowers Y; Bar-Gil Shitrit A; Eliakim R; Ben-Horin S; Roblin X
Aliment Pharmacol Ther; 2017 Jan; 45(2):276-282. PubMed ID: 27862102
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulator use does not prevent first loss of response to anti-tumour necrosis factor alpha therapy in inflammatory bowel disease: long-term outcomes in a real-world cohort.
Varma P; Rajadurai AS; Holt DQ; Devonshire DA; Desmond CP; Swan MP; Nathan D; Shelton ET; Prideaux L; Sorrell C; Rusli F; Crantock LRF; Dev A; Ratnam DT; Pianko S; Moore GT
Intern Med J; 2019 Jun; 49(6):753-760. PubMed ID: 30381884
[TBL] [Abstract][Full Text] [Related]
13. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
[TBL] [Abstract][Full Text] [Related]
14. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
[TBL] [Abstract][Full Text] [Related]
15. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
[TBL] [Abstract][Full Text] [Related]
16. Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis.
Lowell JA; Sharma G; Chua V; Ben-Horin S; Swaminath A; Sultan K
Dig Dis Sci; 2024 Jun; ():. PubMed ID: 38877332
[TBL] [Abstract][Full Text] [Related]
17. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
Roblin X; Williet N; Boschetti G; Phelip JM; Del Tedesco E; Berger AE; Vedrines P; Duru G; Peyrin-Biroulet L; Nancey S; Flourie B; Paul S
Gut; 2020 Jul; 69(7):1206-1212. PubMed ID: 31980448
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes With Adalimumab Therapy in Pediatric Crohn Disease: Associations With Adalimumab Exposure.
Rinawi F; Popalis C; Tersigni C; Frost K; Muise A; Church PC; Walters TD; Ricciuto A; Griffiths AM
J Pediatr Gastroenterol Nutr; 2022 Mar; 74(3):389-395. PubMed ID: 35226647
[TBL] [Abstract][Full Text] [Related]
19. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease.
Kim JY; Lee Y; Choe BH; Kang B
Gut Liver; 2021 Jul; 15(4):588-598. PubMed ID: 33024062
[TBL] [Abstract][Full Text] [Related]
20. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
Yanai H; Lichtenstein L; Assa A; Mazor Y; Weiss B; Levine A; Ron Y; Kopylov U; Bujanover Y; Rosenbach Y; Ungar B; Eliakim R; Chowers Y; Shamir R; Fraser G; Dotan I; Ben-Horin S
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):522-530.e2. PubMed ID: 25066837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
